Notícias

Moby summary of Iovance Biotherapeutics, Inc.'s Q2 2026 earnings call

Iovance Biotherapeutics Inc (IOVA) reports record Q2 2026 revenue of $99.3 million, driven by strong Amtagvi demand and all-time high gross margins of 56%.

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) rocketed to a fresh 52-week high on Thursday, clocking as much as 47 percent gains, after management reported a 66 percent jump in revenues that signaled the strengthening demand for its treatment for advanced melanoma. In intra-day trading, the stock surged to its highest price of $6.39 before trimming gains to […]

Iovance Biotherapeutics (NASDAQ:IOVA) reported record second-quarter revenue and gross margin, driven by demand for its Amtagvi tumor-infiltrating lymphocyte, or TIL, therapy, as the company expanded its treatment-center network and advanced clinical programs in lung cancer, sarcoma and gynecologic

Record quarterly revenue, improving margins and continued commercial momentum are prompting Iovance to reassess its full-year guidance while advancing multiple late-stage clinical programmes. Key Investor TakeawaysIovance Biotherapeutics (NASDAQ:IOVA) reported record second-quarter revenue of approximately $99.

Iovance Biotherapeutics stock has rebounded strongly in the short term, yet its longer track record and current valuation checks paint a more mixed picture that investors need to weigh carefully. After a steep multi year share price decline, the broader valuation framework now points to Iovance as screening cheap on several measures. Iovance Biotherapeutics shares have declined 82.7% over the past 5 years, which highlights how much long term holders have been hurt and why any apparent value...

Iovance Biotherapeutics recently announced it will report its second quarter 2026 results and corporate updates on August 6, 2026, drawing attention as Wall Street anticipates a quarterly loss alongside higher year-over-year revenue. Analysts’ earnings revisions and a negative Earnings ESP highlight uncertainty around the upcoming report, even as interest in Iovance’s TIL-based Amtagvi® therapy and broader pipeline remains elevated. Next, we’ll examine how this upcoming earnings release and...

Iovance Biotherapeutics (IOVA) is drawing attention ahead of its second quarter 2026 earnings report and corporate update scheduled for August 6, 2026, which will be presented alongside its first FDA-approved T cell therapy for solid tumors. See our latest analysis for Iovance Biotherapeutics. The latest pullback in Iovance Biotherapeutics, with a 1-day share price return down 13.22% and 7-day share price return down 18.44% to US$4.07, sits against a stronger backdrop that includes a 30-day...

Neurocrine Biosciences (NASDAQ:NBIX) reported second-quarter 2026 revenue of more than $950 million, nearly 40% higher than a year earlier, as sales of INGREZZA and CRENESSITY continued to grow and the company added a partial-quarter contribution from VYKAT XR following its acquisition of Soleno The

Iovance Biotherapeutics (IOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here is how Apogee Therapeutics Inc. (APGE) and Iovance Biotherapeutics (IOVA) have performed compared to their sector so far this year.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the Best Penny Stocks to Invest In According to Billionaires. Recently, on June 30, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) updated its corporate presentation, highlighting its position as a global leader in tumor-infiltrating lymphocyte cell therapy. ​The update noted that the company has now treated more than 1,500 patients through […]

While Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has gained 54.95% year-to-date, analysts continue to see 112.80% upside, helping it secure a spot on our list of hot biotech stocks under $5 to buy. Two meaningful pipeline and regulatory developments arrived within days of each other, adding fresh momentum to Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)’s expanding TIL therapy platform. […]

Iovance Biotherapeutics (IOVA) is back in focus after Australia’s Therapeutic Goods Administration granted conditional approval for Amtagvi, a tumor infiltrating lymphocyte therapy for previously treated unresectable or metastatic melanoma in a high incidence market. See our latest analysis for Iovance Biotherapeutics. The TGA decision comes after a volatile period, with the stock delivering a 67.86% year to date share price return and a 106.34% total shareholder return over one year...

Iovance Biotherapeutics recently received FDA clearance to proceed with an investigational new drug application for IOV-5001, a next-generation IL-12 tethered tumor infiltrating lymphocyte therapy, enabling a Phase 1/2 trial in advanced colorectal, triple-negative, estrogen receptor-low breast cancers and other solid tumors. The therapy’s design to localize IL-12 expression within tumors, by tethering it to TIL cell surfaces, highlights Iovance’s push to refine efficacy while aiming to limit...

ImmunityBio eyes a steadier path after a 290% YTD surge as investors watch Anktiva demand, FDA review timing and execution risks.

IBRX's Anktiva drives a 668% revenues jump in 2025 as ImmunityBio expands bladder cancer approvals and pursues new catalysts.

Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than Agenus despite higher valuation.

Stock move puts Iovance Biotherapeutics (IOVA) back in focus Iovance Biotherapeutics (IOVA) has drawn attention after recent trading, with the stock closing at $4.11 and posting double-digit total returns over the past month and the past three months. See our latest analysis for Iovance Biotherapeutics. The recent 1-day share price return of 11.08% and 7-day share price return of 19.13%, on top of a 63.10% year to date share price return, point to building momentum, although the 3-year total...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the 10 Best US Stocks Under $5 to Buy. On May 7, Chardan reduced its price target on Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) from $16 to $14 while maintaining a Buy rating on the stock. This update comes after the company’s first-quarter 2026 results. Chardan’s analyst told investors in […]

Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) just released its latest quarterly report and things are not looking...

Iovance Biotherapeutics (NASDAQ:IOVA) reported first-quarter 2026 revenue of $71 million, up roughly 45% year-over-year, as the company pointed to rising demand for its tumor-infiltrating lymphocyte (TIL) therapy AMTAGVI and expanding commercial execution. Management also reiterated that recent manu

Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index decreasing 0.6%

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of 0.00% and -7.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Alvotech (ALVO) delivered earnings and revenue surprises of -28.57% and -22.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Why Iovance Biotherapeutics Stock Is Back on Investors’ Radar Iovance Biotherapeutics (IOVA) is drawing fresh attention after short interest in the stock eased and several large institutions increased positions, hinting at a shift in how the market is approaching the company. This interest arrives alongside a proposal for the June 10, 2026 annual meeting to raise authorized common shares from 500,000,000 to 650,000,000. This is a move that can affect how you think about future financing and...

Iovance Biotherapeutics (IOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Iovance Biotherapeutics, listed as NasdaqGM:IOVA, has proposed a significant increase to its authorized common stock. Shareholders are scheduled to vote on the proposal at the company’s upcoming annual meeting. The authorization change would give the company more flexibility for future equity issuances, subject to board approval. Iovance Biotherapeutics focuses on cell therapies targeting cancer, an area that often requires substantial capital for clinical development, manufacturing...

Regeneron (REGN) delivered earnings and revenue surprises of +11.18% and +4.88%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?